fhd-286
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 10, 2021 (NCT04879017)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- GABA receptor gamma-1 subunitINHIBITOR
GABRG1 inhibitor
SMARCA2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC[C@H](NC(=O)c1ccn(S(C)(=O)=O)c1)C(=O)Nc1nc(-c2cccc(N3C[C@@H](C)O[C@@H](C)C3)n2)cs1- Mol. weight
- 562.67 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095181 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07283094 | Phase 1 | Jan 31, 2026 | Foghorn Therapeutics Inc., Yeshiva University |
| NCT04891757 | Phase 1 | Jun 14, 2021 | Foghorn Therapeutics, Foghorn Therapeutics Inc. |
| NCT04879017 | Phase 1 | May 10, 2021 | Foghorn Therapeutics, Foghorn Therapeutics Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. | For profit | 3 | 2 | 1 | 2021 |
| Foghorn Therapeutics | For profit | 2 | 0 | 1 | 2021 |
| Yeshiva University | Academic/Hospital | 1 | 1 | 1 | 2026 |
3 organizations
Page 1 / 1